Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly. It is a triple agonist: a single molecule that activates three different metabolic receptors at once - GLP-1, GIP, and the glucagon receptor. Phase 2 results published in the New England Journal of Medicine in 2023 reported mean weight loss of around 24% at 48 weeks in the highest-dose arm, the largest figure published for any pharmacologic agent in trials to date.

Shop by goal

Popular compounds

Research resources

What is Retatrutide? The 2026 Research Guide to the Triple-Agonist Peptide

Q: Is retatrutide FDA approved?

No. As of 2026, retatrutide is investigational. It is currently in the Phase 3 TRIUMPH program (Eli Lilly), with multiple registered trials on ClinicalTrials.gov. FDA approval is not expected before completion of those Phase 3 trials. It is not approved by the FDA, EMA, MHRA, or any other major regulator.

Q: How does retatrutide work?

Retatrutide simultaneously activates three receptors involved in metabolic control. GLP-1 receptor activation slows gastric emptying and central appetite. GIP receptor activation supports insulin secretion and adipose tissue handling. Glucagon receptor activation increases energy expenditure - a mechanism the GLP-1-only and GLP-1/GIP dual-agonist classes don't engage. The triple mechanism is the basis for the unusually large weight-loss effect observed in trials.

Q: How does retatrutide compare to semaglutide and tirzepatide?

Semaglutide (Ozempic, Wegovy) is a single-receptor GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP agonist. Retatrutide adds the third glucagon receptor on top, which explains the higher reported weight-loss percentages in trials. Direct head-to-head trials between all three are limited; comparative inference is based on separate trial cohorts and is not equivalent to a randomised comparison.

Q: Where can I buy retatrutide for research?

Because retatrutide is investigational and unlicensed, no pharmacy or clinic can sell it; laboratories source it from research-compound suppliers that publish a per-batch Certificate of Analysis and label material research use only. New-U Research Compounds catalogues research-grade retatrutide as Retatrutide - sealed 10-vial packs of lyophilised reference peptide verified to >99% HPLC purity by Janoshik and Freedom Diagnostics, with tracked worldwide delivery. Research use only, not for human consumption.

Q: How much does research retatrutide cost?

Research-grade retatrutide (catalogued as Retatrutide) is priced per vial in USD and scales by mg per vial across tiers from 5 mg up to 60 mg, so the per-mg cost falls on larger vials. Every tier ships in sealed 10-vial packs at >99% HPLC purity with a per-batch Certificate of Analysis; shipping is free over $300, with card and cryptocurrency accepted.

Retatrutide is the most-watched investigational peptide in metabolic research right now. Search interest jumped roughly 8x in 12 months, the Phase 2 results published in the New England Journal of Medicine reported the largest weight-loss percentage ever recorded for a pharmacologic agent in trials, and the Phase 3 TRIUMPH program is currently enrolling thousands of participants across multiple indications. This is a plain-English research guide to what it is, how it works, and where the evidence actually sits.

RUO framing throughout. New-U supplies retatrutide strictly as a laboratory reagent under our Retatrutide SKU. It is investigational, not approved by FDA / EMA / MHRA, and not for human consumption or weight-loss application. Clinical-trial outcomes do not transfer outside the trial context.

The One-Sentence Answer

Retatrutide (development code LY3437943 , by Eli Lilly) is a synthetic peptide that simultaneously activates three metabolic receptors in a single molecule: GLP-1 , GIP , and the glucagon receptor . That triple-agonist mechanism is what separates it from every approved drug in the category.

How Retatrutide Compares to the Approved GLP-1 Family

Compound Receptor targets Approval status Trial weight-loss % Semaglutide (Ozempic, Wegovy) GLP-1 only FDA approved (2017 T2D; 2021 obesity) ~15% at 68 weeks (STEP-1) Tirzepatide (Mounjaro, Zepbound) GLP-1 + GIP (dual) FDA approved (2022 T2D; 2023 obesity) ~22.5% at 72 weeks (SURMOUNT-1, 15mg) Retatrutide GLP-1 + GIP + Glucagon (triple) Investigational, Phase 3 ongoing ~24.2% at 48 weeks (Phase 2, 12mg)

The retatrutide Phase 2 number (24.2%, Jastreboff et al., NEJM 2023) is striking partly because it was achieved in 48 weeks , faster than the comparable semaglutide and tirzepatide endpoints (68 and 72 weeks respectively). Phase 3 outcomes are pending; clinical-trial evidence does not establish what would happen outside the trial protocol.

What "Triple Agonist" Actually Means

The molecule is engineered to bind and activate three receptors at once. Each contributes to the overall metabolic effect:

GLP-1 receptor - slows gastric emptying, suppresses appetite via central nervous system signalling, improves insulin secretion. This is the mechanism the entire GLP-1 class (semaglutide, liraglutide, dulaglutide) relies on.

GIP receptor - the "incretin" partner. Enhances insulin secretion in a glucose-dependent way, supports lipid handling in adipose tissue. This is the second receptor tirzepatide adds.

Glucagon receptor - this is the novel one. Activates hepatic glucose output but also increases resting energy expenditure - the body burns more calories at baseline. The dual GLP-1/GIP class doesn't engage this pathway.

The hypothesis is that the third receptor closes the loop on energy balance: GLP-1 + GIP reduce intake, glucagon raises expenditure. The Phase 2 data is consistent with that hypothesis. Phase 3 evidence will test whether the effect holds at scale.

The Trial Landscape

Retatrutide is being tested across multiple indications in the TRIUMPH Phase 3 program. The registered trials cover:

TRIUMPH-1 - adults with obesity (no diabetes)

TRIUMPH-2 - adults with obesity and type 2 diabetes

TRIUMPH-3 - obesity with cardiovascular disease

TRIUMPH-4 - obesity and knee osteoarthritis

TRIUMPH-5 - metabolic dysfunction-associated steatotic liver disease (MASLD)

For the full breakdown of the Phase 3 evidence base and what each trial is measuring, see our companion piece on the retatrutide Phase 3 TRIUMPH program.

Where the Search Interest Is Coming From

Semrush US-Google data through May 2026 shows search volume for "what is retatrutide" up roughly 8x over the prior 12 months. The fastest-rising related queries:

Query Vol/mo (US) 12-month trend what is retatrutide 5,400 +750% (0.12 to 1.00) how long will 10mg of retatrutide last 2,900 rising is retatrutide safe 1,900 rising where to buy retatrutide 1,900 rising how to get retatrutide 1,600 rising how to reconstitute retatrutide 1,300 rising is retatrutide FDA approved 1,000 rising

For why so much of that demand is being captured by research-compound channels rather than clinical trial enrolment, see our piece on retatrutide online sourcing trends.

What the Research Literature Reports

The primary Phase 2 publication (Jastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial , NEJM, August 2023) ran 338 adults with obesity over 48 weeks. Reported outcomes at the highest 12mg dose:

~24.2% mean weight loss vs ~2.1% placebo

~100% of participants in the 8mg+ arms achieved ≥5% weight loss

~83% in the 12mg arm achieved ≥15% weight loss

~26% in the 12mg arm achieved ≥25% weight loss at 48 weeks

Improvements in blood pressure, HbA1c, triglycerides, liver fat (where measured)

Reported adverse events were predominantly gastrointestinal (nausea, diarrhoea, vomiting) and dose-dependent, consistent with the broader GLP-1 class. For the full outcomes breakdown including dose-response curves and how the numbers compare to semaglutide and tirzepatide Phase 3 endpoints, see retatrutide weight-loss percentage results.

Investigational status. Retatrutide is not approved by the FDA, EMA, MHRA, or any other major medicines regulator as of 2026. Phase 3 (TRIUMPH) is ongoing. Any retatrutide outside an active clinical trial is supplied as a research-grade reagent only and is not licensed for human consumption, weight-loss application, or any therapeutic purpose. It is also on the WADA Prohibited List (S2) and banned in any sanctioned competition.

The Honest Picture for Research Buyers

The mechanism case is the most sophisticated in the modern peptide pipeline. Three receptors, complementary targets, biologically defensible hypothesis.

The Phase 2 trial evidence is genuinely striking. ~24% weight loss in 48 weeks is the largest figure in the published pharmacological literature for any single agent.

The Phase 3 evidence is still pending. TRIUMPH-1 readouts are expected in late 2026 / 2027.

The regulatory status is unambiguous: investigational, not approved, research-grade only outside trials.

The verification step is non-negotiable. Retatrutide is a 39-amino-acid peptide with a complex fatty-acid modification; counterfeits and underdosed product are documented. Third-party COAs (Janoshik, Freedom Diagnostics) are the only defence - how to read a COA.

Frequently Asked Questions

What is retatrutide? Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly. It is a triple agonist - a single molecule that activates the GLP-1, GIP and glucagon receptors at once. Phase 2 results (NEJM, 2023) reported mean weight loss of around 24% at 48 weeks in the highest-dose arm, the largest figure published for any pharmacologic agent in trials to date.

Is retatrutide FDA approved? No. As of 2026 retatrutide is investigational, currently in the Phase 3 TRIUMPH program with multiple registered trials on ClinicalTrials.gov. It is not approved by the FDA, EMA, MHRA or any other major regulator.

How does retatrutide work? It activates three metabolic receptors simultaneously: GLP-1 (slows gastric emptying and central appetite), GIP (supports insulin secretion and adipose handling), and glucagon (increases energy expenditure - a mechanism the GLP-1-only and dual-agonist classes don’t engage). The triple mechanism is the basis for the unusually large weight-loss effect seen in trials.

How does retatrutide compare to semaglutide and tirzepatide? Semaglutide (Ozempic, Wegovy) is single-receptor GLP-1. Tirzepatide (Mounjaro, Zepbound) is dual GLP-1/GIP. Retatrutide adds the third glucagon receptor on top, which explains the higher reported weight-loss percentages. Head-to-head trials are limited, so cross-trial comparison is not equivalent to a randomised comparison.

Where can I buy retatrutide for research? Because retatrutide is unlicensed, no pharmacy or clinic can sell it - laboratories source it from research-compound suppliers that publish a per-batch CoA and label material research use only. New-U catalogues research-grade retatrutide as Retatrutide: sealed 10-vial packs verified to >99% HPLC purity by Janoshik and Freedom Diagnostics, tracked worldwide. Research use only.

How much does research retatrutide cost? It is priced per vial in USD and scales by mg per vial from 5 mg up to 60 mg, so the per-mg cost drops on larger vials. Every tier ships in sealed 10-vial packs at >99% HPLC purity with a per-batch CoA; free shipping over $300, card and crypto accepted. See the retatrutide product page for current per-vial pricing.

From the Lab - Peptides on LinkedIn & Facebook

Retatrutide, Lab-Verified.

Sealed vials of research-grade retatrutide, independently HPLC-verified at >99% purity by Janoshik and Freedom Diagnostics. Research use only - not for human consumption. Investigational compound, WADA-prohibited in sanctioned competition.

Research-grade · >99% HPLC purity · COA per lot

Buy Retatrutide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

What is Retatrutide? The 2026 Research Guide to the Triple-Agonist Peptide

The One-Sentence Answer

How Retatrutide Compares to the Approved GLP-1 Family

What "Triple Agonist" Actually Means

The Trial Landscape

Where the Search Interest Is Coming From

What the Research Literature Reports

The Honest Picture for Research Buyers

Related Reading

Frequently Asked Questions

From the Lab - Peptides on LinkedIn & Facebook

Retatrutide, Lab-Verified.

Buy Retatrutide from New-U Research Compounds

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide